David Steensma, MD
David Steensma, MD, FACP, has served as the Global Head of Hematology in the Novartis Institutes for Biomedical Research (NIBR) in Cambridge, Massachusetts since December 2020, leading early clinical development across hematological malignancies and non-malignant hematology. After medical school at the University of Chicago-Pritzker School of Medicine, he trained as a hematologist and medical oncologist at Mayo Clinic, spent several years as research scholar focused on globin gene regulation at the Weatherall Institute of Molecular Medicine at the University of Oxford, and served on the faculty at Mayo for 7 years before joining Dana-Farber Cancer Institute and Harvard Medical School in 2009.
At Dana-Farber, he was the Edward P. Evans Professor of Myelodysplastic Syndromes and director the Center for Prevention of Progression of Hematological Malignancies; at Harvard he co-directed a new course in stem cell biology and regenerative medicine. He has served on the Food and Drug Administration Oncology Drugs Advisory Committee (FDA ODAC), Education Chair for the American Society of Hematology (ASH), editor of several ASH publications including ASH Clinical News, and Art of Oncology section editor of the Journal of Clinical Oncology, and published >450 articles on topics in hematology, hematopathology and medical history.